Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Adjei, C. Erlichman, J. Sloan, J. Reid, H. Pitot, R. Goldberg, P. Peethambaram, P. Atherton, L. Hanson, S. Alberts, J. Jett (2000)
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 8
F. Shepherd, J. Pereira, J. Pawel, U. Gatzemeier, T. Tsao, N. Hanna, R. Rosell, P. Paoletti, S. Paul, P. Bunn, L. Einhorn (2003)
PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapyLung Cancer, 41
J. Symanowski, J. Rusthoven, N. Vogelzang (2005)
P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression modelLung Cancer, 49
M. Pistolesi, J. Symanowski, U. Gatzemeier, S. Emri, P. Conte, C. Manegold, N. Levitan, J. Blatter, P. Paoletti (2003)
P-513 Improving pulmonary function in patients with malignant pleural mesothelioma: Results of the phase III trial of pemetrexed + cisplatin vs. cisplatinLung Cancer, 41
C. Manegold, U. Gatzemeier, J. Pawel, R. Pirker, R. Malayeri, J. Blatter, K. Krejcy (2000)
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.Annals of oncology : official journal of the European Society for Medical Oncology, 11 4
R.G. Zinner, C.K. Obasaju, F.V. Fossella (2003)
A phase II trial of Alimta plus carboplatin in patients with advanced non-small cell lung cancerLung Cancer, 41
D. Rinaldi, John Kuhn, Howard Burris, F. Dorr, G. Rodriguez, S. Eckhardt, Suzanne Jones, James Woodworth, S. Baker, C. Langley, D. Mascorro, T. Abrahams, D. Hoff (1999)
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 44
Yanhua Wang, R. Zhao, S. Chattopadhyay, I. Goldman (2002)
A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.Cancer research, 62 22
N. Hanna, S. Paul, F. Demarinis, F. Fossella, M. Salzberg, T. Mueller, F. Shepherd, B. Nguyen, L. Kayitalire, P. Bunn, L. Einhorn (2003)
O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)Lung Cancer, 41
F.A. Shepherd, J. Dancey, A. Arnold (2001)
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials GroupCancer, 92
G. Scagliotti, C. Kortsik, C. Manegold, G. Dark, L. Crinò, M. O'Brien, R. Rosell, L. Kayitalire, S. Paul, L. Paz-Ares (2003)
O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer, 41
N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, P. Paoletti (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
J. Rusthoven, E. Eisenhauer, C. Butts, R. Gregg, J. Dancey, B. Fisher, J. Iglesias (1999)
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 4
R. Bueno, K. Appasani, H. Mercer, S. Lester, D. Sugarbaker (2001)
The α folate receptor is highly activated in malignant pleural mesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 121
J. Rusthoven, E. Eisenhauer, C. Butts (1999)
Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II studyJ Clin Oncol, 17
A. Hughes, P. Calvert, A. Azzabi, R. Plummer, Robert Johnson, J. Rusthoven, M. Griffin, K. Fishwick, A. Boddy, M. Verrill, H. Calvert (2002)
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
S. Clarke, R. Abratt, L. Goedhals, M. Boyer, M. Millward, S. Ackland (2002)
Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 13 5
E. Vokes, L. Szeto, A. Mauer, S. Krauss, C. Rudin, L. Kayitalire, P. Hoffman, D. Haraf (2003)
O-308 A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small-cell lung cancer or esophageal cancerLung Cancer, 41
E. Smit, K. Mattson, J. Pawel, C. Manegold, Stephen Clarke, P. Postmus (2003)
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 14 3
R. Zinner, C. Obasaju, F. Fossella, K. Pisters, V. Papadimitrakopoulou, B. Varghese, B. Peeples, A. Hatfield, W. Hong, R. Herbst (2003)
P-522 A phase II trial of Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)Lung Cancer, 41
C. Niyikiza, S. Baker, D. Seitz, J. Walling, K. Nelson, J. Rusthoven, S. Stabler, P. Paoletti, A. Calvert, R. Allen (2002)
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.Molecular cancer therapeutics, 1 7
R. Thödtmann, H. Depenbrock, H. Dumez, J. Blatter, R. Johnson, A. Oosterom, A. Hanauske (1999)
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 10
M. Pistolesi, J. Synamowski, U. Gatzemeier (2003)
Improving function in patients with malignant pleural mesothelioma: results of a phase III trial of pemetrexed + cisplatin versus cisplatinLung Cancer, 41
D. Coffey (2002)
Understanding the Cancer Biology Universe: Enigmas, Context and Future ProspectsCancer Biology & Therapy, 1
G. Scagliotti, D. Shin, H. Kindler, M. Vasconcelles, U. Keppler, C. Manegold, H. Burris, U. Gatzemeier, J. Blatter, J. Symanowski, J. Rusthoven (2003)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 8
D.S. Ettinger, C. Monnerat, K. Kelly (2002)
Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: importance of survival over responseProc Am Soc Clin Oncol, 21
J. Symanowski, J. Rusthoven, B. Nguyen (2003)
Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesotheliomaProc Am Soc Clin Oncol, 22
F. Shepherd, J. Dancey, A. Arnold, A. Neville, J. Rusthoven, Robert Johnson, B. Fisher, E. Eisenhauer (2001)
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinomaCancer, 92
M. Boyer, J. Jassem, A. Liepa, J. Symanowski, E. Kaukel, C. Denham, L. Paz-Ares, R. Gralla, P. Hnllen, B. Nguyen (2003)
O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesotheliomaLung Cancer, 41
Review of current data on pemetrexed (Alimta® ) in the treatment of lung cancer
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.